Union Inks China Deal For Promising Skin Drug Orismilast
A Potential Rival To Amgen's Otezla
Innovent is paying the Danish biotech $20m upfront for the China rights to the mid-stage PDE4 inhibitor that is being developed for psoriasis, atopic dermatitis and hidradenitis suppurativa.
